• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Pharmaceutical Product Development, Inc. (PPD) is a global contract research organization engaged in providing drug discovery and development services, post-approval expertise and compound partnering programs. The Discovery Sciences Group focuses on the discovery research segment of the biopharmaceutical research and development outsourcing market. The Development Group has designed its various global services to be integrated in order to assist its clients in optimizing their research and development spending through the clinical stages of the development process. The Development Group provides a range of development services to meet clients' needs. In addition, for marketed drugs, biologics and devices, PPD offers support services, such as product launch services, medical information, patient compliance programs, patient and disease registry programs, product safety and pharmacovigilance, Phase IV monitored studies and prescription-to-over-the-counter programs.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
ESHELMAN FREDRIC N EXECUTIVE CHAIRMAN |
|
No longer subject to file | 2011-12-05 | 0 |
|
No longer subject to file | 2011-12-05 | 0 | |
|
No longer subject to file | 2011-12-05 | 0 | |
|
No longer subject to file | 2011-12-05 | 0 | |
|
No longer subject to file | 2011-12-05 | 0 | |
|
HARTMAN JUDD GENERAL COUNSEL |
|
No longer subject to file | 2011-12-05 | 0 |
|
No longer subject to file | 2011-12-05 | 0 | |
|
No longer subject to file | 2011-12-05 | 0 | |
|
No longer subject to file | 2011-12-05 | 0 | |
|
RICHARDSON WILLIAM W SR. VP GLOBAL BUS. DEVELOPMENT |
|
No longer subject to file | 2011-12-05 | 0 |
|
SHARBAUGH WILLIAM J CHIEF OPERATING OFFICER |
|
No longer subject to file | 2011-12-05 | 0 |
|
DARAZSDI DANIEL G CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2011-12-05 | 0 |
|
WILKINSON MICHAEL O. CHIEF INFORMATION OFFICER |
|
No longer subject to file | 2011-12-05 | 0 |
|
DINGIVAN CHRISTINE A EVP/CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2011-12-05 | 0 |
|
BABISS LEE EXEC. VP--GLOBAL LAB SERVICES |
|
No longer subject to file | 2011-12-05 | 0 |
|
COLVIN PAUL EVP--CLINICAL DEVELOPMENT |
|
No longer subject to file | 2011-12-05 | 0 |
|
HILL RAYMOND H CHIEF EXECUTIVE OFFICER |
|
No longer subject to file | 2011-12-05 | 0 |
|
GRANGE DAVID L CHIEF EXECUTIVE OFFICER |
|
61,045 | 2011-02-28 | 0 |
|
3,069,770 | 2011-02-24 | 0 | |
|
16,199 | 2011-01-03 | 0 | |
|
WILKINSON PETER J VP OF FIN./CHIEF ACCTG. OFF. |
|
828 | 2008-12-31 | 0 |
|
COVINGTON PAUL S EXECUTIVE VICE PRESIDENT |
|
881 | 2008-06-30 | 0 |
|
BADDOUR LINDA CHIEF FINANCIAL OFFICER |
|
174,943 | 2007-06-01 | 0 |
|
50,772 | 2007-05-16 | 0 | |
|
SHANNON COLIN EVP, GLOBAL CLINICAL OPS |
|
125,000 | 2007-05-04 | 0 |
|
DAVENPORT FRED B JR PRESIDENT |
|
242,732 | 2006-12-18 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
